医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Best’s Commentary: Thailand Insurers Offer Innovative Vaccine Allergy Product, But Underwriting Risks Remain

2021年10月08日 AM10:00
このエントリーをはてなブックマークに追加


 

SINGAPORE

Vaccine allergy insurance products launched by Thailand insurers address an important financial protection need in the Southeast Asian country, and presents a good opportunity for business growth; however, AM Best notes the importance of prudent risk management that accompany any new product development.

In its Best’s Commentary, “Thailand Insurers Offer Innovative Vaccine Allergy Product, But Underwriting Risks Remain,” AM Best states that with new variants having emerged, coupled with pockets of vaccine hesitancy, the recent introduction of vaccine allergy insurance cover provides a growth opportunity for Thailand’s life and non-life insurance segments, which were supported by robust health insurance demand in 2020.

While domestic insurers in Thailand have been swift to capitalise on market opportunities amid the pandemic, AM Best notes the importance of insurers remaining on top of their risk exposure, given the uncertainty surrounding loss exposure. Effective risk mitigation will need to be supported by prudent underwriting risk management, including appropriate use of reinsurance; effective pricing strategies; clearly defined policy coverages; and prudent limits that are aligned to the companies’ risk appetites.

Insurers will need to stay abreast of vaccine-related developments related to frequency and severity trends of side effects domestically and globally in order to proactively manage and limit their risk exposure should adverse trends develop. COVID-19 vaccine profiles vary among manufacturers, and the World Health Organization has noted a lack of comprehensive quality data regarding the serious adverse effects of particular vaccines. Positive or negative developments in these areas could bear material implications for Thailand insurers offering vaccine allergy insurance cover.

To access the full copy of this commentary, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=313424.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2021 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005987/en/

CONTACT

Chris Lim

Senior Financial Analyst

+65 6303 5018

chris.lim@ambest.com

Myles Gould

Director, Analytics

+65 6303 5020

myles.gould@ambest.com

Christopher Sharkey

Manager, Public Relations

+1 908 439 2200, ext. 5159

christopher.sharkey@ambest.com

Jim Peavy

Director, Communications

+1 908 439 2200, ext. 5644

james.peavy@ambest.com

同じカテゴリーの記事 

  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial